AbbVie ABBV underwent analysis by 17 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
---|---|---|---|---|---|
Total Ratings | 5 | 8 | 4 | 0 | 0 |
Last 30D | 1 | 0 | 0 | 0 | 0 |
1M Ago | 0 | 1 | 1 | 0 | 0 |
2M Ago | 1 | 5 | 0 | 0 | 0 |
3M Ago | 3 | 2 | 3 | 0 | 0 |
Analysts have set 12-month price targets for AbbVie, revealing an average target of $211.24, a high estimate of $231.00, and a low estimate of $191.00. This current average has increased by 0.55% from the previous average price target of $210.08.
Diving into Analyst Ratings: An In-Depth Exploration
The standing of AbbVie among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
---|---|---|---|---|---|
Srikripa Devarakonda | Truist Securities | Lowers | Buy | $211.00 | $215.00 |
Christopher Raymond | Piper Sandler | Raises | Overweight | $220.00 | $212.00 |
Tim Anderson | B of A Securities | Announces | Neutral | $191.00 | - |
David Risinger | Leerink Partners | Announces | Outperform | $206.00 | - |
Alexandria Hammond | Wolfe Research | Announces | Outperform | $205.00 | - |
Chris Schott | JP Morgan | Lowers | Overweight | $200.00 | $210.00 |
Geoff Meacham | Citigroup | Lowers | Buy | $215.00 | $226.00 |
Evan David Seigerman | BMO Capital | Lowers | Outperform | $208.00 | $228.00 |
Terence Flynn | Morgan Stanley | Lowers | Overweight | $224.00 | $231.00 |
Vamil Divan | Guggenheim | Raises | Buy | $221.00 | $212.00 |
Geoff Meacham | Citigroup | Raises | Buy | $226.00 | $215.00 |
Navin Jacob | UBS | Raises | Neutral | $200.00 | $195.00 |
Terence Flynn | Morgan Stanley | Raises | Overweight | $231.00 | $218.00 |
Andrew Baum | Citigroup | Raises | Buy | $215.00 | $170.00 |
Geoff Meacham | B of A Securities | Raises | Neutral | $195.00 | $185.00 |
Evan David Seigerman | BMO Capital | Raises | Outperform | $220.00 | $214.00 |
Aaron Gal | Bernstein | Announces | Market Perform | $203.00 | - |
Key Insights:
- Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to AbbVie. This information provides a snapshot of how analysts perceive the current state of the company.
- Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of AbbVie compared to the broader market.
- Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of AbbVie's market standing. Stay informed and make data-driven decisions with our Ratings Table.
Stay up to date on AbbVie analyst ratings.
Get to Know AbbVie Better
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics (including Botox).
AbbVie: Financial Performance Dissected
Market Capitalization Analysis: With a profound presence, the company's market capitalization is above industry averages. This reflects substantial size and strong market recognition.
Positive Revenue Trend: Examining AbbVie's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 3.83% as of 30 September, 2024, showcasing a substantial increase in top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: AbbVie's net margin is impressive, surpassing industry averages. With a net margin of 10.73%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): AbbVie's ROE excels beyond industry benchmarks, reaching 24.22%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): AbbVie's ROA excels beyond industry benchmarks, reaching 1.09%. This signifies efficient management of assets and strong financial health.
Debt Management: AbbVie's debt-to-equity ratio stands notably higher than the industry average, reaching 11.78. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.
The Significance of Analyst Ratings Explained
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. Click here to stay ahead of the market.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.